Introduction {#Sec1}
============

Severe sepsis and septic shock are commonly complicated by myocardial dysfunction, even in patients without pre-existing coronary artery disease \[[@CR1], [@CR2]\], and cardiac failure may contribute to poor outcome in these patients \[[@CR1], [@CR2]\]. Early recognition of myocardial injury and ventricular dysfunction in severe sepsis and septic shock may improve short-term prognosis, but is difficult to diagnose \[[@CR3]\].

Cardiac troponins T (cTnT) and I (cTnI) are components of the myofibrillar contractile apparatus of cardiomyocytes. Measurement of troponins is routinely used for diagnosis of myocardial necrosis in patients with suspected acute coronary syndromes \[[@CR4], [@CR5]\], and to identify patients benefiting from early medical and coronary interventions \[[@CR6], [@CR7]\]. Recently, several studies have also reported detectable cTnT or cTnI levels in patients with sepsis, but their predictive value has not been firmly established \[[@CR8]--[@CR16]\]. Explanations for the diverging results regarding utility of troponin testing in sepsis may be inadequate sample size and use of troponin assays with limited sensitivity and precision in the low concentration range \[[@CR8]--[@CR16]\]. However, a new and highly sensitive assay for cTnT (hs-cTnT) measurement now allows detection of concentrations tenfold lower than with previous assays \[[@CR17]\]. The clinical benefit of using this novel hs-cTnT assay has been demonstrated in patients with stable coronary artery disease and preserved left ventricular function, as the hs-cTnT assay detected measurable levels of troponin T in 97.7% of these patients, and improved risk stratification beyond standard patient evaluation \[[@CR18]\]. In contrast, only 1.3% of these patients would have had measurable levels of cTnT with the conventional fourth-generation assay.

Accordingly, we hypothesized that hs-cTnT would be detectable in a high proportion of patients with sepsis or septic shock, be associated with conventional risk markers in sepsis, and provide superior prognostic information compared to a conventional fourth-generation cTnT assay.

Materials and methods {#Sec2}
=====================

Study design {#Sec3}
------------

The study is a substudy of FINNSEPSIS, a prospective observational cohort study of the incidence and prognosis of sepsis in 24 intensive care units (ICUs) in Finland \[[@CR19], [@CR20]\]. In brief, all patients aged 18 years or older admitted to the ICUs of participating centres were screened daily for the American College of Chest Physicians/Society of Critical Care Medicine criteria of severe sepsis or septic shock. All patients fulfilling the criteria, i.e. known or suspected infection, with two or more criteria for systemic inflammatory response syndrome, and at least one new, sepsis-induced organ failure, were included in the FINNSEPSIS cohort. Previous diagnosis of cardiovascular disease (defined as either a history of heart failure or coronary artery disease requiring medication or former disease-associated procedure), hypertension, or diabetes mellitus was collected from patient chart records. Peak creatinine and lactate levels, the lowest platelet count, and maximal dose of vasoactive drugs infused during the first 24 h after inclusion were also recorded. After the first 24 h, the simplified acute physiology score (SAPS) II was recorded \[[@CR21]\]. The sequential organ failure assessment (SOFA) was subsequently scored daily \[[@CR22]\]. All data were collected and transferred via internet to the Finnish intensive care quality consortium (Intensium, Kuopio, Finland). In-hospital mortality was recorded and classified as the primary endpoint. Patients were screened daily for septic shock during the ICU stay, and shock was considered a secondary endpoint. The FINNSEPSIS study and all substudies have been approved by the Regional Ethics Committees at each participating centre, and the study was performed according to the Declaration of Helsinki.

Biochemical analyses {#Sec4}
--------------------

For this biomarker substudy, patients were included if written informed consent for blood sampling could be obtained from the patient or a relative, and if laboratory samples were available from both inclusion in the study and 72 h thereafter (Fig. [1](#Fig1){ref-type="fig"}). Blood sampling was performed from indwelling arterial catheters or by venipuncture \[[@CR23], [@CR24]\]. The samples were centrifuged at room temperature and the serum component was aspirated and frozen at −20°C at individual centres. Within 3 months of collection, plasma samples were shipped on dry ice to the Helsinki University Hospital for storage at −80°C for 4 years pending analysis at Akershus University Hospital.Fig. 1Flow chart for the study

hs-cTnT and cTnT levels were determined on an autoanalyzer (Cobas e 411) using only commercial assays (Roche Diagnostics, Penzberg, Germany). The hs-cTnT assay utilizes the same antibodies as the conventional fourth-generation assay \[[@CR17]\]. The lower detection level of the hs-cTnT assay is 0.003 μg/L, and the 99th percentile value with less than 10% coefficient of variance (CV) in healthy subjects is 0.014 μg/L. The corresponding detection limit for the fourth-generation assay is 0.01 μg/L, and the 99th percentile value with less than 10% CV is 0.03 μg/L. The laboratory personnel were blinded to patients clinical information.

Estimated glomerulal filtration rate (eGFR) was calculated by the MDRD formula \[[@CR25]\], N-terminal pro-B-type natriuretic peptide (NT-proBNP) was analysed as previously described \[[@CR24]\], and body mass index (BMI) was calculated as weight (kg)/height (m)^2^.

Statistical analyses {#Sec5}
--------------------

Data are presented as median (quartile (Q) 1--3) or absolute values and percentages. We assessed differences between groups by the Mann--Whitney *U* test for continuous variables as most were not normally distributed, while categorical data were compared by the Fisher exact test. Associations between variables were assessed by Spearman rank correlation. Variables associated with hs-TnT levels (logarithmic transformation) on inclusion were evaluated by multivariate linear regression analysis with age, gender, previous cardiovascular disease, hypertension, diabetes, BMI, NT-proBNP, eGFR, and peak lactate levels and lowest platelet count within the first 24 h from inclusion in the model (logarithmic transformation for the last four variables). Odds ratios (OR) with 95% confidence interval (CI) for in-hospital mortality were calculated by logistic regression analysis. Because of skewed distributions, troponin T measurements were entered after logarithmic transformation. Predictive factors that were significant in univariate analysis were included in a multivariate model using a forward selection procedure. Receiver operating characteristics (ROC) curve analysis was used for identification of optimal cut-off points and to examine discrimination, and areas under the curve (AUCs with 95% CI) were compared \[[@CR26]\]. *P* values less than 0.05 were considered significant for all analyses. Statistical analyses were performed with SPSS for Windows version 14.0 (SPSS, Chicago, IL) with the exception of the comparison of ROC AUCs, which was performed with MedCalc for Windows, version 9.5.1.0 (MedCalc Software, Mariakerke, Belgium) and the statistical programming language R (R Development Core Team, 2008).

Results {#Sec6}
=======

Patient characteristics {#Sec7}
-----------------------

We included all patients who gave written informed consent and for whom blood samples were available at both time points examined: (1) inclusion in this study and (2) 72 h thereafter. This accounted for 207 out of the 470 patients (44%) from the FINNSEPSIS cohort (Fig. [1](#Fig1){ref-type="fig"}). Median duration from diagnosis of sepsis to blood sampling was 9 h (Q1--3, 3--17 h). Of these 207 patients, 47 (23%) died in the hospital. Characteristics of the patients according to in-hospital mortality are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of the study patients according to in-hospital survival statusVariableNon-survivors (*n* = 47)Survivors (*n* = 160)*P* valueAge65 (56--76)58 (47--70)0.001Male sex27 (57%)114 (71%)0.079Body mass index25 (23--27)26 (23--29)0.36Cardiovascular disease19 (40%)34 (21%)0.012Diabetes12 (26%)31(19%)0.41Hypertension16 (34%)59 (37%)0.73Positive blood culture12 (26%)45 (28%)0.85Ventilator treatment41 (86%)114 (71%)0.034Peak creatinine levels in 24 h (μmol/L)128 (66--275)98 (70--159)0.10Lowest eGFR in 24 h (mg/min)38 (19--92)68 (39--99)0.04Peak lactate levels in 24 h (mmol/L)2.9 (1.6--4.0)1.9 (1.1--3.1)0.02Lowest platelet count in 24 h (×10^9^/L)126 (87--234)148 (88--267)0.52SAPS II score51 (39--60)41 (31--50)\<0.001SOFA score9 (7--13)8 (6--10)0.0134th gen cTnT on inclusion (μg/L)0.04 (0.00--0.21)0.02 (0.00--0.09)0.14hs-cTnT on inclusion (μg/L)0.054 (0.022--0.227)0.036 (0.015--0.111)0.047NT-proBNP on inclusion (pg/mL)7,374 (1,308--16,917)3,631 (1,256--9,208)0.114th gen cTnT at 72 h (μg/L)0.03 (0.00--0.20)0.01 (0.00--0.08)0.11hs-cTnT at 72 h (μg/L)0.054 (0.019--0.224)0.035 (0.015--0.093)0.054NT--proBNP at 72 h (pg/mL)5,516 (1,364--17,241)2,231 (616--6,110)0.03*eGFR* estimated glomerular filtration rate; *SAPS II* simplified acute physiology score II; *SOFA* sequential organ failure assessment score; *hs-cTnT* highly sensitive assay for cardiac troponin T; *NT-proBNP* N-terminal pro-B type natriuretic peptide

Cardiac-specific troponins {#Sec8}
--------------------------

cTnT measured by the fourth-generation assay was not detectable in 83 (40%) of the patients on inclusion in the study, while 87 patients (43%) had undetectable levels 72 h after inclusion. In contrast, cTnT measured by the highly sensitive assay was detectable in all patients at both time points. On inclusion, hs-cTnT levels ranged from 0.004 to 13.577 μg/L (median 0.039 μg/L \[Q1--3, 0.017--0.135 μg/L\]), whereas after 72 h concentrations ranged from 0.003 to 6.580 μg/L (median 0.037 μg/L \[Q1--3, 0.016--0.109 μg/L\]). Median cTnT levels measured by the fourth-generation assay were 0.02 μg/L at both time points (Q1--3, 0.00--0.11 and 0.00--0.09 μg/L, respectively). On inclusion, 166 patients (80%) had cTnT levels over the normal 99th percentile value according to the hs-cTnT assay (\>0.014 μg/L) versus 86 patients (42%) according to the fourth-generation cTnT assay (\>0.03 μg/L) (Supplementary Figure). Similarly, hs-cTnT levels were elevated in 161 patients (of 204, 79%) 72 h after inclusion compared to 14 patients (7%) according to the fourth-generation assay (Supplementary Figure). Characteristics of the patients according to hs-cTnT elevation on inclusion in this study are shown in the online supplementary material (Supplementary Table 1).

A correlation was observed between hs-cTnT levels on inclusion and after 72 h (*n* = 204; *r* = 0.82, *P* \< 0.001). hs-cTnT levels on inclusion were also correlated with severity of disease (SAPS II score, *r* = 0.27, *P* \< 0.001), multiple organ dysfunction (SOFA score, *r* = 0.30, *P* \< 0.001), creatinine level (*r* = 0.32, *P* \< 0.001), age (*r* = 0.22, *P* = 0.002), and peak 24-h dose of dobutamine (*r* = 0.15, *P* = 0.03) and noradrenalin (*r* = 0.19, *P* = 0.007). Elevated NT-proBNP levels on inclusion (*P* \< 0.001), previous cardiovascular disease (*P* = 0.005), and increased BMI levels (*P* = 0.015) were associated with high levels of hs-cTnT on study inclusion, whereas there was no significant association with patient age, gender, hypertension, diabetes, platelet count, eGFR or lactate levels (Supplementary Table 2). The model of NT-proBNP levels, previous cardiovascular disease, and BMI explained 42% of the variance in hs-cTnT levels (*r*^2^ = 0.42).

Troponin T levels and in-hospital mortality {#Sec9}
-------------------------------------------

The median hs-cTnT level on inclusion in this study was higher in hospital non-survivors than in survivors: 0.054 (Q1--3, 0.022--0.227) versus 0.035 (0.015--0.111) μg/L, *P* = 0.047 (Fig. [2](#Fig2){ref-type="fig"}), while the fourth-generation assay did not differentiate between hospital non-survivors and survivors: 0.04 (0.00--0.21) versus 0.02 (0.00--0.09) μg/L, *P* = 0.14. cTnT levels after 72 h were not different for patients surviving to hospital discharge and non-survivors, either measured by the highly sensitive assay: 0.054 (0.019--0.224) versus 0.035 (0.015--0.093) μg/L, *P* = 0.054, or by the fourth-generation assay: 0.03 (0.00--0.20) versus 0.01 (0.00--0.08) μg/L, *P* = 0.11. Change in cTnT levels from inclusion in this study to 72 h was not associated with in-hospital mortality: neither according to the high sensitivity assay: non-survivors: 0.001 (−0.033 to 0.015) versus survivors: −0.004 (−0.028 to 0.003) μg/L (*P* = 0.63), nor the fourth-generation cTnT assay: non-survivors: 0.00 (−0.03 to 0.02) versus survivors: 0.00 (−0.02 to 0.00) μg/L (*P* = 0.52). In the subgroup of patients with moderate severity of disease (inframedian SAPS II score \<47 points, *n* = 97), hs-cTnT levels were not different in hospital non-survivors (*n* = 15) compared to survivors (*n* = 82): 0.042 (0.018--0.242) versus 0.030 (0.012--0.098) μg/L (*P* = 0.17). In patients with undetectable cTnT levels with the fourth-generation assay on inclusion (*n* = 83), no significant differences in hs-cTnT levels in non-survivors (*n* = 16) versus survivors (*n* = 67) were found: 0.017 (0.011--0.023) versus 0.014 (0.008--0.021) (*P* = 0.11).Fig. 2hs-cTnT levels on inclusion in this study and 72 h thereafter in patients surviving to hospital discharge and in non-survivors. The *horizontal line* within the *box* represents the median level, the*boundaries* of the *box* quartiles 1--3, and the*whiskers* range (maximum value restricted to 1.5× interquartile range from the median). ^*\#*^*P* \< 0.05

By univariate logistic regression, inclusion hs-cTnT levels (OR 1.29 \[95% CI 1.03--1.60\]) and levels after 72 h (OR 1.28 \[1.04--1.58\]) were both associated with in-hospital mortality (Table [2](#Tab2){ref-type="table"}). AUCs for hs-cTnT on study inclusion and after 72 h were comparable: AUC 0.588 (95% CI 0.517--0.656) vs. 0.593 (0.522--0.661). Inclusion or 72 h cTnT measured by the fourth-generation assay was not associated with in-hospital mortality: ORs 1.12 \[95% CI 0.98--1.27\] and 1.12 \[0.99--1.28\], respectively).Table 2Predictors for in-hospital mortality by univariate and multivariate logistic regression analysisOdds ratio95% CI*p*Univariate analysis Age, per 1 year increase1.051.02--1.070.001 Gender (female vs. male)1.840.94--3.600.08 Body mass index, per 1 unit increase0.980.91--1.050.52 Cardiovascular disease2.571.28--5.160.008 Diabetes1.430.67--3.060.36 Hypertension0.880.44--1.730.70 Positive blood culture0.880.42--1.840.73 eGFR, per 1 unit increase0.590.37--0.920.02 Lactate, per 1 unit increase1.731.04--2.880.04 Platelet count, per 1 unit increase0.910.63--1.320.62 SAPS II score after 24 h, per 1 unit increase1.051.02--1.07\<0.001 SOFA score after 24 h, per 1 unit increase1.171.05--1.290.003 hs-cTnT on inclusion, per 1 unit increase1.291.03--1.600.024 4th gen cTnT on inclusion, per 1 unit increase1.120.98--1.270.10 hs-cTnT at 72 h, per 1 unit increase1.281.04--1.580.019 4th gen cTnT at 72 h, per 1 unit increase1.120.99--1.280.07Multivariate analysis: final model SAPS II score, per 1 unit increase1.051.02--1.080.001*eGFR* estimated glomerular filtration rate; *hs-cTnT* highly sensitive assay for cardiac troponin T; *SAPS II* simplified acute physiology score II; *SOFA* sequential organ failure assessment score; *eGFR* estimated glomerular filtration rate; *hs-cTnT* highly sensitive assay for cardiac troponin T

After adjustment for age, previous cardiovascular disease, eGFR, peak lactate levels, SAPS II and SOFA scores in multivariate analysis, neither hs-cTnT nor cTnT measured by the fourth-generation assay was associated with in-hospital mortality (*P* values 0.26 and 0.65, respectively; Table [2](#Tab2){ref-type="table"}). Furthermore, the addition of cTnT measurement to SAPS II score did not improve discrimination between hospital survivors and non-survivors: AUC = 0.678 for SAPS II score alone, AUC = 0.685 for SAPS II plus fourth-generation cTnT assay, and AUC = 0.684 for SAPS II plus hs-cTnT, both *P* = 0.45 vs. SAPS II alone (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Prognostic accuracy of in-hospital mortality for SAPS II score alone and in combination with troponin T measurements by either the highly sensitive assay or the established fourth-generation assay

Troponin T levels and septic shock {#Sec10}
----------------------------------

hs-cTnT levels on inclusion in this study were higher in patients with septic shock during the hospitalization compared to those without shock: 0.044 (Q1--3, 0.024--0.171) versus 0.033 (0.012--0.103) μg/L (*P* = 0.03; Fig. [4](#Fig4){ref-type="fig"}). In contrast, cTnT levels measured by the fourth-generation assay were comparable: 0.02 (0.00--0.15) versus 0.01 (0.00--0.09) μg/L (*P* = 0.10), as were NT-proBNP levels on inclusion: 4,809 (2,064--9,782) versus 3,631 (764--12,351) pg/mL (*P* = 0.17; Fig. [4](#Fig4){ref-type="fig"}). The optimal cut-off for hs-cTnT to predict septic shock during the hospitalization (86% sensitivity, 33% specificity) was 0.014 μg/L. Cut-off points for the fourth-generation cTnT assay and NT-proBNP on inclusion were 0.01 μg/L (58% sensitivity, 51% specificity) and 785 pg/mL (90% sensitivity, 26% specificity), respectively. In a multivariate model adjusting for other cardiac biomarkers and information that were available on inclusion in this study (Supplementary Table 3), hs-cTnT greater than 0.014 μg/L was independently associated with shock during the hospitalization (OR 2.45 \[95% CI 1.09--5.53\], *P* = 0.03).Fig. 4hs-cTnT and NT-proBNP levels on inclusion in this study in patients with circulatory failure and non-failure during the index hospitalization. The *horizontal line* within the *box* represents the median level, the*boundaries* of the *box* quartiles 1--3, and the*whiskers* range (maximum value restricted to 1.5× interquartile range from the median). ^*\#*^*P* \< 0.05

Discussion {#Sec11}
==========

The novel findings of the current study of a large cohort of patients with severe sepsis are that (1) detectable levels of cTnT are present in all patients according to the new highly sensitive assay, whereas detectable levels were observed in 60% of patients by using a conventional assay; (2) hs-cTnT correlated with disease severity in severe sepsis and septic shock; and (3) although hs-cTnT levels were significantly higher in hospital non-survivors than in survivors, the discriminatory ability was only modest; and (4) hs-cTnT levels may have greatest potential in assessing risk for septic shock.

Several studies have reported an association between troponin levels, measured by conventional assays and short-term outcome in severe sepsis or septic shock \[[@CR8], [@CR9], [@CR12], [@CR13], [@CR15], [@CR27]\], whereas others have shown no relationship \[[@CR10], [@CR16]\]. Recently, a study of a cohort of 159 patients with bacteraemia reported that cTnI measured with a conventional assay is a univariate, but not an independent predictor of outcome \[[@CR14]\]. In another study with 218 paediatric septic or septic shock patients the same pattern was observed \[[@CR28]\]. The current study, which to our knowledge is the first to evaluate the novel highly sensitive assay and includes the largest cohort of adult septic patients with troponin measurements, confirms and extends the data regarding short-term risk stratification in severe sepsis. Moreover, the study results suggest that hs-cTnT measurement, despite reflecting cardiomyocyte injury, does not reliably identify non-surviving patients. Thus, although we used a highly sensitive cTnT assay, closely associated with traditional indices of risk, and identified low-level myocardial troponin release in a greater proportion of patients than the traditional fourth-generation troponin assay, this did not translate into significantly improved prediction of in-hospital mortality. This was also the case in subgroups of patients with intermediate risk and in the patients that had undetectable cTnT levels as measured by the fourth-generation assay. The lack of information regarding mortality could be attributable to myocardial dysfunction not being the principal mode of death in patients with severe sepsis, thus also diminishing the merit of hs-cTnT as a marker of mortality in sepsis. In contrast, hs-cTnT may still be of use in patients with severe sepsis for detection of shock. Interestingly, we found that the previously recognized hs-cTnT 99th percentile level of 0.014 μg/L in the general population was superior to other cardiac biomarkers and clinical variables for prediction of shock. Thus, a cTnT level less than 0.014 μg/L in the early stage of severe sepsis may be useful to identify patients with low risk of shock, which is in line with a strategy previously also proposed for NT-proBNP \[[@CR29]\]. Still, this result needs to be confirmed in future studies, and especially in studies that also compare hs-cTnT measurement to echocardiographic findings.

As the cardiac-specific troponins differ from skeletal muscle-derived troponin isoforms, detection of cTnI and cTnT in the circulation has generally been considered a sensitive and specific marker of cardiomyocyte necrosis, and these proteins are today routinely used in the clinical context of acute coronary syndromes \[[@CR4], [@CR5]\]. Although a low-grade elevation of circulating troponin T levels can also be found in healthy individuals after strenuous physical exercise \[[@CR30]\], the association between hs-cTnT levels and septic shock in our patients points to a role for hs-cTnT in sepsis as an indicator of myocardial function and circulatory status. This is also supported by a close association between hs-cTnT and NT-proBNP levels, and the higher hs-cTnT levels found in patients with established cardiovascular disease. Interestingly, elevated troponin levels have also been detected in other cardiac and non-cardiac conditions, including acute and chronic heart failure \[[@CR31], [@CR32]\], renal failure \[[@CR33]\], chronic obstructive pulmonary disease \[[@CR34], [@CR35]\], pulmonary embolism \[[@CR36]\], and sepsis \[[@CR8]--[@CR16], [@CR27], [@CR28], [@CR37]\]. The mechanism for troponin elevation in these conditions may not be an acute coronary artery occlusion, but rather low-grade cardiomyocyte injury due to an unfavourable myocardial milieu \[[@CR1], [@CR2], [@CR37]\]. Still, earlier studies of patients with sepsis have reported an association between troponin elevation and left ventricular dysfunction, as assessed by echocardiography and pulmonary artery catheterization \[[@CR8]--[@CR10], [@CR12]\]. Potential contributing factors to troponin elevation in this setting are reduced myocardial blood flow secondary to arterial hypotension, microvascular thrombosis with subsequent myocardial injury and augmented myocardial apoptosis secondary to pro-inflammatory cytokines, including tumour necrosis factor-α, interleukin-1β, and interleukin-6 \[[@CR1], [@CR2]\]. Moreover, troponin release in sepsis does not necessarily indicate cardiomyocyte necrosis, but could also be a result of increased cell permeability and the release of troponin degradation products through the cell membrane in non-necrotic cardiomyocytes \[[@CR38]\]. The value of troponin measurement for assessing myocardial function and cardiovascular status is supported by our study, but it should be recognized that diverging results have been reported for the cytokine-mediated troponin release \[[@CR39]\] and the alleged impaired coronary blood flow in patients with septic shock \[[@CR40]\].

Our study has some limitations. First, because of the exclusion of early deaths patients with consent for blood samples at both time points had slightly lower in-hospital mortality compared to all participants in the FINNSEPSIS study. Second, we were not able to include any objective measures of cardiac function, such as echocardiography. Finally, no assessment of coronary anatomy was performed, thus precluding assessment of the contribution of coronary stenosis to troponin elevation. Furthermore, these data do not translate to any conclusions for troponin I, as the mechanism for release and frequency of elevation may be different. The timing of blood sampling may also have affected the results for troponin measurement, although our daily screening strategy ensured that a high proportion of the samples were obtained early after start of sepsis.

In conclusion, we found that the novel highly sensitive assay detects circulating troponin T in all patients with severe sepsis, and that hs-cTnT levels are correlated with indices of poor prognosis in sepsis, but does not add to SAPS II score for prediction of in-hospital mortality. In contrast, hs-cTnT levels in the early phase of sepsis seem to provide interesting information regarding shock, and the major use of hs-cTnT measurement in sepsis could possibly be to stratify patients regarding risk of shock. Still, this needs to be verified in additional studies, and also compared to objective measures of cardiac function, as assessed by echocardiography or other imaging modalities.
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On behalf of the FINNSEPSIS Study Group. A complete list of the investigators who participated in the study is presented in "[Appendix 1](#Sec12){ref-type="sec"}".
